Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
EXEL or INCY: Which Is the Better Value Stock Right Now?
12:46pm, Monday, 09'th Dec 2024
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investors?
2 Biotech Stocks to Buy Hand Over Fist in December
08:45am, Saturday, 07'th Dec 2024
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
10:57am, Friday, 29'th Nov 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 28'th Nov 2024
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
04:05pm, Wednesday, 27'th Nov 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in December: Piper Sand
ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion
12:30pm, Wednesday, 27'th Nov 2024
The FDA notified EXEL that its sNDA seeking label expansion of cabozantinib will be discussed at an ODAC meeting in March 2025.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sN
End of Year Rally: 3 Stocks to Watch (IDCC, FUTU, EXEL)
01:35pm, Tuesday, 26'th Nov 2024
As the calendar winds down, the stock market often heats up. The last five weeks of the year have historically shown a bullish seasonal pattern, fueled by holiday optimism, institutional portfolio adj
Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?
02:25pm, Monday, 25'th Nov 2024
EXEL's shares move north 25% in a month on the back of strong third-quarter results and raised outlook. We are optimistic about the stock as we believe there is room for growth.
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
10:45am, Monday, 25'th Nov 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Reasons Growth Investors Will Love Exelixis (EXEL)
01:46pm, Thursday, 21'st Nov 2024
Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
12:41pm, Thursday, 21'st Nov 2024
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks presents investors with t
Looking for Earnings Beat? Buy These 4 Top-Ranked Stocks
08:20am, Tuesday, 19'th Nov 2024
Top-ranked stocks Amazon.com (AMZN), Maplebear Inc. (CART), Exelixis (EXEL) and Doximity (DOCS) are likely to beat on the bottom line in their upcoming releases.
What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now?
01:06pm, Monday, 11'th Nov 2024
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
10:51am, Monday, 11'th Nov 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
